271 related articles for article (PubMed ID: 25363551)
41. Overlapping and distinct expression of progesterone receptors A and B in mouse uterus and mammary gland during the estrous cycle.
Mote PA; Arnett-Mansfield RL; Gava N; deFazio A; Mulac-Jericevic B; Conneely OM; Clarke CL
Endocrinology; 2006 Dec; 147(12):5503-12. PubMed ID: 16980438
[TBL] [Abstract][Full Text] [Related]
42. Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21.
Musgrove EA; Lee CS; Cornish AL; Swarbrick A; Sutherland RL
Mol Endocrinol; 1997 Jan; 11(1):54-66. PubMed ID: 8994188
[TBL] [Abstract][Full Text] [Related]
43. Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells.
Proietti C; Salatino M; Rosemblit C; Carnevale R; Pecci A; Kornblihtt AR; Molinolo AA; Frahm I; Charreau EH; Schillaci R; Elizalde PV
Mol Cell Biol; 2005 Jun; 25(12):4826-40. PubMed ID: 15923602
[TBL] [Abstract][Full Text] [Related]
44. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression.
Knutson TP; Daniel AR; Fan D; Silverstein KA; Covington KR; Fuqua SA; Lange CA
Breast Cancer Res; 2012 Jun; 14(3):R95. PubMed ID: 22697792
[TBL] [Abstract][Full Text] [Related]
45. Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients.
Pathiraja TN; Shetty PB; Jelinek J; He R; Hartmaier R; Margossian AL; Hilsenbeck SG; Issa JP; Oesterreich S
Clin Cancer Res; 2011 Jun; 17(12):4177-86. PubMed ID: 21459801
[TBL] [Abstract][Full Text] [Related]
46. G protein pathway suppressor 2 (GPS2) is a transcriptional corepressor important for estrogen receptor alpha-mediated transcriptional regulation.
Cheng X; Kao HY
J Biol Chem; 2009 Dec; 284(52):36395-36404. PubMed ID: 19858209
[TBL] [Abstract][Full Text] [Related]
47. Complex agonist-like properties of ICI 182,780 (Faslodex) in human breast cancer cells that predominantly express progesterone receptor-B: implications for treatment resistance.
Wu J; Liang Y; Nawaz Z; Hyder SM
Int J Oncol; 2005 Dec; 27(6):1647-59. PubMed ID: 16273221
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
[TBL] [Abstract][Full Text] [Related]
49. Differential hormonal regulation and function of progesterone receptor isoforms in normal adult mouse mammary gland.
Aupperlee MD; Haslam SZ
Endocrinology; 2007 May; 148(5):2290-300. PubMed ID: 17317767
[TBL] [Abstract][Full Text] [Related]
50. Classical membrane progesterone receptors in murine mammary carcinomas: agonistic effects of progestins and RU-486 mediating rapid non-genomic effects.
Bottino MC; Cerliani JP; Rojas P; Giulianelli S; Soldati R; Mondillo C; Gorostiaga MA; Pignataro OP; Calvo JC; Gutkind JS; Panomwat Amornphimoltham ; Molinolo AA; Lüthy IA; Lanari C
Breast Cancer Res Treat; 2011 Apr; 126(3):621-36. PubMed ID: 20535544
[TBL] [Abstract][Full Text] [Related]
51. The antiprogestin RU38 486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells.
Horwitz KB
Endocrinology; 1985 Jun; 116(6):2236-45. PubMed ID: 4039656
[TBL] [Abstract][Full Text] [Related]
52. Mechanism of BRCA1-mediated inhibition of progesterone receptor transcriptional activity.
Katiyar P; Ma Y; Riegel A; Fan S; Rosen EM
Mol Endocrinol; 2009 Aug; 23(8):1135-46. PubMed ID: 19389812
[TBL] [Abstract][Full Text] [Related]
53. New antiprogestins with partial agonist activity: potential selective progesterone receptor modulators (SPRMs) and probes for receptor- and coregulator-induced changes in progesterone receptor induction properties.
Giannoukos G; Szapary D; Smith CL; Meeker JE; Simons SS
Mol Endocrinol; 2001 Feb; 15(2):255-70. PubMed ID: 11158332
[TBL] [Abstract][Full Text] [Related]
54. Cytoskeletal responsiveness to progestins is dependent on progesterone receptor A levels.
McGowan EM; Weinberger RP; Graham JD; Hill HD; Hughes JA; O'Neill GM; Clarke CL
J Mol Endocrinol; 2003 Oct; 31(2):241-53. PubMed ID: 14519093
[TBL] [Abstract][Full Text] [Related]
55. Isoform specificity of progesterone receptor antibodies.
Fabris V; Abascal MF; Giulianelli S; May M; Sequeira GR; Jacobsen B; Lombès M; Han J; Tran L; Molinolo A; Lanari C
J Pathol Clin Res; 2017 Oct; 3(4):227-233. PubMed ID: 29085663
[TBL] [Abstract][Full Text] [Related]
56. Reproductive epidemiology of glial tumors may reveal novel treatments: high-dose progestins or progesterone antagonists as endocrino-immune modifiers against glioma.
Altinoz MA; Ozpinar A; Elmaci I
Neurosurg Rev; 2019 Jun; 42(2):351-369. PubMed ID: 29453736
[TBL] [Abstract][Full Text] [Related]
57. Progesterone-induced inhibition of growth and differential regulation of gene expression in PRA- and/or PRB-expressing endometrial cancer cell lines.
Smid-Koopman E; Kuhne LC; Hanekamp EE; Gielen SC; De Ruiter PE; Grootegoed JA; Helmerhorst TJ; Burger CW; Brinkmann AO; Huikeshoven FJ; Blok LJ
J Soc Gynecol Investig; 2005 May; 12(4):285-92. PubMed ID: 15866122
[TBL] [Abstract][Full Text] [Related]
58. Alterations in Progesterone Receptor Isoform Balance in Normal and Neoplastic Breast Cells Modulates the Stem Cell Population.
Recouvreux MS; Diaz Bessone MI; Taruselli A; Todaro L; Lago Huvelle MA; Sampayo RG; Bissell MJ; Simian M
Cells; 2020 Sep; 9(9):. PubMed ID: 32932770
[TBL] [Abstract][Full Text] [Related]
59. Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells.
Dressing GE; Knutson TP; Schiewer MJ; Daniel AR; Hagan CR; Diep CH; Knudsen KE; Lange CA
Mol Endocrinol; 2014 Apr; 28(4):442-57. PubMed ID: 24606123
[TBL] [Abstract][Full Text] [Related]
60. Ulipristal Acetate Inhibits Progesterone Receptor Isoform A-Mediated Human Breast Cancer Proliferation and BCl2-L1 Expression.
Esber N; Le Billan F; Resche-Rigon M; Loosfelt H; Lombès M; Chabbert-Buffet N
PLoS One; 2015; 10(10):e0140795. PubMed ID: 26474308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
